Board Refresh and CEO Resignation
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Arovella Therapeutics Limited has announced a board refresh and the resignation of its CEO, Dr. Michael Baker, following a notice from a shareholder to remove certain directors. Dr. Baker will remain in his position for three months, while Dr. Andrew Nash, Dr. Debora Barton, and Dr. Mike Perry have resigned immediately. The new board will focus on reviewing the company's technology platform and growth opportunities to create long-term value for shareholders. Mr. David Williams has been appointed as the new Chairman of the Board.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- CLDN18.2 CAR iNKT Cell Preclinical Data Update
- Half Year Report and Appendix 4D
- ALA's ind for ALA-101 accepted by the U.S.FDA
- Quarterly Activities/Appendix 4C Cash Flow Report
- Arovella Therapeutics appoints former CSL CSO Dr Andrew Nash as Non-executive Director
Later from Arovella Therapeutics
- Arovella Appoints Acting CEO
- Clinical manufacturing batch released, first site activated
- The path to first patient dosing
- Second Clinical Batch Released for Immediate Patient Use
- Arovella receives R&D tax rebate of $4.03 million
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics